Roche Unveils Game-Changing CGM to Combat Hypoglycemia in Europe

Roche is preparing to launch its first continuous glucose monitor (CGM), the Accu-Chek Smartguide, in the Netherlands, Switzerland, and Germany in the coming weeks. This innovative device, designed to predict hypoglycaemia and forecast glucose levels, represents a major leap forward in diabetes management. The rollout follows the device’s CE mark approval in July, signaling its potential to reshape diabetes care across Europe.

The Accu-Chek Smartguide, with a battery life of up to 14 days, features predictive algorithms that distinguish it from existing monitors on the market. These include a tool that predicts low blood glucose within 30 minutes and a two-hour glucose forecast, particularly beneficial for managing night-time hypoglycaemia. With over 40% of Type 1 diabetes patients experiencing hypoglycaemia during the night, this advanced technology aims to provide a safer, more reliable solution.

The launch comes as continuous glucose monitoring becomes an essential component of diabetes care. By using machine learning models based on multiple days of patient data, Roche aims to deliver a more accurate and personalized experience. The device is also integrated with Roche’s MySugr app, enhancing usability for patients.

Roche’s Accu-Chek Smartguide is set to make a significant impact on the European diabetes market with its predictive capabilities and user-friendly design. As Roche pursues FDA approval for the U.S. and explores pediatric applications, this launch could herald a new era in diabetes management, offering patients greater control and peace of mind.